Progesterone Preeclampsia

Starting soon · Phase 4

Conditions studied: Preeclampsia, Hypertensive Disorder of Pregnancy

In brief

This randomized controlled trial evaluates whether nightly vaginal micronized progesterone (400 mg) initiated before 12 weeks' gestation reduces the incidence of preeclampsia in low-risk pregnant individuals. Participants will be randomly assigned (1:1) to receive either vaginal progesterone through 16 weeks' gestation or routine prenatal care without progesterone. Maternal and neonatal outcomes-including development of preeclampsia, obstetric complications, gestational diabetes, preterm birth, and neonatal morbidity-will be collected via chart review. The study aims to determine whether early progesterone supplementation decreases the risk of preeclampsia.

Key facts

Study ID

NCT07448597

Run by

Medical University of South Carolina

People needed

642

Starts

2026-08-01

Expected to finish

2028-05-01

Last updated by the study team

2026-05-29

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Pregnant individuals receiving prenatal care at participating clinics
• <12 weeks gestation with a viable intrauterine pregnancy
• Age ≥18 years
• English-speaking

You may not qualify if…

• Unable or unwilling to self-administer vaginal progesterone
• Inability or unwillingness to provide informed consent

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.